Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
(2020) In Clinical Gastroenterology and Hepatology 18(10). p.2-2304- Abstract
Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical... (More)
Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. Results: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P =.035). Factors associated with lower ALP were normal ALP at baseline (P <.01), treatment with adalimumab (P =.090), and treatment in Europe (P =.083). Conclusions: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Anti-Inflammatory, Hepatic, Intestine, Liver Transplantation
- in
- Clinical Gastroenterology and Hepatology
- volume
- 18
- issue
- 10
- pages
- 2 - 2304
- publisher
- Elsevier
- external identifiers
-
- pmid:32068151
- scopus:85082932202
- ISSN
- 1542-3565
- DOI
- 10.1016/j.cgh.2020.02.014
- language
- English
- LU publication?
- yes
- id
- 4f5a16a9-bb9a-47cd-9c23-f693ec016e9f
- date added to LUP
- 2021-01-08 13:36:15
- date last changed
- 2024-09-19 13:05:36
@article{4f5a16a9-bb9a-47cd-9c23-f693ec016e9f, abstract = {{<p>Background & Aims: Few patients with primary sclerosing cholangitis (PSC) and inflammatory bowel diseases (IBDs) are exposed to tumor necrosis factor (TNF) antagonists because of the often mild symptoms of IBD. We assessed the effects of anti-TNF agents on liver function in patients with PSC and IBD, and their efficacy in treatment of IBD. Methods: We performed a retrospective analysis of 141 patients with PSC and IBD receiving treatment with anti-TNF agents (infliximab or adalimumab) at 20 sites (mostly tertiary-care centers) in Europe and North America. We collected data on the serum level of alkaline phosphatase (ALP). IBD response was defined as either endoscopic response or, if no endoscopic data were available, clinical response, as determined by the treating clinician or measurements of fecal calprotectin. Remission was defined more stringently as endoscopic mucosal healing. We used linear regression analysis to identify factors associated significantly with level of ALP during anti-TNF therapy. Results: Anti-TNF treatment produced a response of IBD in 48% of patients and remission of IBD in 23%. There was no difference in PSC symptom frequency before or after drug exposure. The most common reasons for anti-TNF discontinuation were primary nonresponse of IBD (17%) and side effects (18%). At 3 months, infliximab-treated patients had a median reduction in serum level of ALP of 4% (interquartile range, reduction of 25% to increase of 19%) compared with a median 15% reduction in ALP in adalimumab-treated patients (interquartile range, reduction of 29% to reduction of 4%; P =.035). Factors associated with lower ALP were normal ALP at baseline (P <.01), treatment with adalimumab (P =.090), and treatment in Europe (P =.083). Conclusions: In a retrospective analysis of 141 patients with PSC and IBD, anti-TNF agents were moderately effective and were not associated with exacerbation of PSC symptoms or specific side effects. Prospective studies are needed to investigate the association between use of adalimumab and reduced serum levels of ALP further.</p>}}, author = {{Hedin, Charlotte Rose Hawkey and Sado, Gina and Ndegwa, Nelson and Lytvyak, Ellina and Mason, Andrew and Montano-Loza, Aldo and Gerussi, Alessio and Saffioti, Francesca and Thorburn, Douglas and Nilsson, Emma and Larsson, Geir and Moum, Bjørn A. and van Munster, Kim N. and Ponsioen, Cyriel Y. and Levy, Cynthia and Nogueira, Nicholas F. and Bowlus, Christopher L. and Gotlieb, Neta and Shibolet, Oren and Lynch, Kate D. and Chapman, Roger W. and Rupp, Christian and Vesterhus, Mette and Jørgensen, Kristin K. and Rorsman, Fredrik and Schramm, Christoph and Sabino, João and Vermeire, Severine and Zago, Alessandra and Cazzagon, Nora and Marschall, Hanns Ulrich and Ytting, Henriette and Ben Belkacem, Karima and Chazouilleres, Olivier and Almer, Sven and Bergquist, Annika}}, issn = {{1542-3565}}, keywords = {{Anti-Inflammatory; Hepatic; Intestine; Liver Transplantation}}, language = {{eng}}, number = {{10}}, pages = {{2--2304}}, publisher = {{Elsevier}}, series = {{Clinical Gastroenterology and Hepatology}}, title = {{Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis}}, url = {{http://dx.doi.org/10.1016/j.cgh.2020.02.014}}, doi = {{10.1016/j.cgh.2020.02.014}}, volume = {{18}}, year = {{2020}}, }